Clinical adverse events to letairis: a real-world drug safety study based on FDA adverse event reporting system (FAERS)

Background Letairis (ambrisentan), an endothelin receptor antagonist (ERA), is a critical medication for pulmonary arterial hypertension (PAH). Despite its efficacy, its safety profile is under scrutiny, warranting a detailed analysis.